UBS Raises Regeneron (REGN) Price Target, Maintains Neutral Rating

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. UBS analyst Trung Huynh raised the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $584 from $560 while maintaining a Neutral rating ahead of the company’s second-quarter earnings report.

UBS Raises Regeneron (REGN) Price Target, Maintaining Neutral Rating

A pharmacist in a lab coat carefully analyzing a vial of medicine for its quality.

The move reflects slightly more optimistic expectations for Regeneron’s financial performance, particularly driven by the continued strength of its flagship eye treatment, Eylea. The franchise has shown resilience amid increased competition in the ophthalmology space, and investor attention is likely to focus on how well Regeneron has defended its market share.

Despite the upward revision, UBS remains cautious on the stock, pointing to a balance of risks and rewards in the near term. While the company has a robust pipeline and strong positioning in its core therapeutic areas, the firm believes the current share price already reflects much of the near-term optimism.

The note also signals that while the broader biotech sector has experienced renewed investor interest, Regeneron’s valuation leaves limited room for upside unless new catalysts emerge. The stock has performed steadily in recent months, and the upcoming earnings release may serve as a key moment for reassessing momentum into the second half of the year.

While we acknowledge the potential of REGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than REGN and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: Top 10 Healthcare AI Stocks to Buy According to Hedge Funds and 10 Consumer Defensive Stocks to Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.